7 active not recruiting, 5 completed, 4 recruiting, 1 suspended. 18 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 18 | Active not recruiting 7, Completed 5, Recruiting 4, Suspended 1, Terminated 1 |
| Phase 2 | 5 | Active not recruiting 2, Completed 1, Recruiting 1, Suspended 1 |
Follow peposertib: new trials by email Literature Review of peposertib trials Research Report on peposertib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm | Phase 1 | Recruiting | National Cancer Institute (NCI) | 66 | 2024-06-07 | 2026-08-24 |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma Biopsy Procedure, Biospecimen Collection, Computed Tomography - Metastatic Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 30 | 2024-02-06 | 2026-10-22 |
| Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors 89Zr-TLX250, 177Lu-TLX250 and Peposertib - Solid Tumor, Adult, Advanced Solid Tumor | Phase 1 | Recruiting | Telix Pharmaceuticals (Innovations) Pty Limited | 36 | 2023-05-23 | 2024-05-01 |
| Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients With Advanced Head and Neck Cancer Who Cannot Take Cisplatin Intensity-Modulated Radiation Therapy, Peposertib - Advanced Head and Neck Squamous Cell Carcinoma, Advanced Hypopharyngeal Squamous Cell Carcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 21 | 2021-12-20 | 2026-10-13 |
| Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Pancreatic Neuroendocrine Tumors Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate - Neuroendocrine Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 29 | 2021-07-22 | 2026-06-15 |
| Effect of Food on Peposertib PK Peposertib - Healthy | Phase 1 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | 12 | 2021-01-14 | 2021-05-12 |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 | Phase 1 / Phase 2 | Suspended | National Cancer Institute (NCI) | 92 | 2021-01-11 | 2026-10-20 |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy Avelumab, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 90 | 2020-10-14 | 2026-10-07 |
| Phase I Trial of DNA-PK Inhibitor (PEPOSERTIB ) in Combination With Radiation and Adjuvant Temozolomide in Newly Diagnosed MGMT Unmethylated and Recurrent Glioblastoma Peposertib, Radiation Therapy, Resection - Glioblastoma, Gliosarcoma | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 29 | 2020-09-20 | 2026-10-16 |
| A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Biospecimen Collection, Computed Tomography, Echocardiography Test - Endometrial High Grade Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 55 | 2020-05-07 | 2026-07-20 |
| Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia Biospecimen Collection, Bone Marrow Biopsy, Cytarabine - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 48 | 2020-05-05 | 2026-06-11 |
| Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Avelumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Malignant Solid Neoplasm, Locally Advanced Unresectable Cholangiocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 103 | 2020-04-07 | 2026-10-02 |
| Study of Peposertib in Combination With Capecitabine and RT in Rectal Cancer Peposertib 50 mg, Peposertib 100 mg, Peposertib 150 mg - Locally Advanced Rectal Cancer | Phase 1 / Phase 2 | Completed | EMD Serono Research & Development Institute, Inc. | 19 | 2019-03-20 | 2023-03-21 |
| Study of Avelumab-M3814 Combinations M3814, Avelumab, Radiotherapy - Oncology, Solid Tumors | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 57 | 2018-11-27 | 2025-04-10 |
| Phase Ib/II Study of M3814 With Etoposide and Cisplatin in Small Cell Lung Cancer (SCLC) Extensive Disease (ED) M3814, Cisplatin, Etoposide - Small Cell Lung Cancer | Phase 1 | Terminated | EMD Serono Research & Development Institute, Inc. | 2 | 2017-05-25 | 2020-09-16 |
| European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors Ribociclib, Topotecan, Temozolomide - Pediatric Cancer | Phase 1 / Phase 2 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 472 | 2016-08-03 | 2026-07-10 |
| Phase 1 Trial of MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Combination With Radiotherapy M3814 100 mg, M3814 200 mg, M3814 300 mg - Advanced Solid Tumors | Phase 1 | Completed | EMD Serono Research & Development Institute, Inc. | 52 | 2015-09-15 | 2024-10-15 |
| Clinical Phase I Study Investigating MSC2490484A, an Inhibitor of a DNA-dependent Protein Kinase, in Advanced Solid Tumors or Chronic Lymphocytic Leukemia MSC2490484A (M3814) - Advanced Solid Tumors, Chronic Lymphocytic Leukemia | Phase 1 | Completed | Merck KGaA, Darmstadt, Germany | 31 | 2014-12-31 | 2020-04-28 |
Neoplasms (3) · Neoplasm Metastasis (2) · Carcinoma (1) · Cholangiocarcinoma (1) · Dermatofibrosarcoma (1) · Fallopian Tube Neoplasms (1) · Gallbladder Neoplasms (1) · Glioblastoma (1) · Gliosarcoma (1) · Histiocytoma, Malignant Fibrous (1) · Hypopharyngeal Neoplasms (1) · Laryngeal Neoplasms (1) · Leiomyosarcoma (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myeloid, Acute (1)
National Cancer Institute (NCI) (9) · EMD Serono Research & Development Institute, Inc. (4) · Gustave Roussy, Cancer Campus, Grand Paris (1) · M.D. Anderson Cancer Center (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · Merck KGaA, Darmstadt, Germany (1) · Telix Pharmaceuticals (Innovations) Pty Limited (1)
United States (14) · Denmark (4) · Belgium (3) · Germany (3) · Netherlands (3) · Spain (3) · Italy (2) · United Kingdom (2) · Australia (1) · Bulgaria (1) · Canada (1) · Czechia (1) · France (1) · Hungary (1) · Norway (1)
Birgit Geoerger, MD (1) · Brian A Jonas (1) · Candace L Haddox (1) · Gregory M Cote (1) · Kristen R Spencer (1) · Lowell B Anthony (1) · Maura L Gillison (1) · Nazanin Majd, MD (1) · Rachel N Grisham (1) · Russell K Pachynski (1) · Sarah L Davis (1)
PMID 31538815, PMID 33230210, PMID 33892407, PMID 34347542, PMID 34543871, PMID 35205614, PMID 35292802, PMID 37905356, PMID 39884775, PMID 41838385, PMID 42686334
UM1CA186691 (2), UM1CA186709 (2), 2014 (1), 2015 (1), 2016 (1), 2018 (1), U10CA180868 (1), UM1CA186644 (1), UM1CA186689 (1), UM1CA186704 (1), UM1CA186712 (1), UM1CA186716 (1), UM1CA186717 (1)